{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:25:42Z","timestamp":1789025142573,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00262-023-03514-3","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T18:02:30Z","timestamp":1691431350000},"page":"3861-3865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19\/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"72","author":[{"given":"Yutaka","family":"Shimazu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadakazu","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"3514_CR1","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/sj.leu.2402890","volume":"17","author":"A L\u00f6ffler","year":"2003","unstructured":"L\u00f6ffler A, Gruen M, Wuchter C et al (2003) Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19\/anti-CD3 single-chain antibody construct. Leukemia 17:900\u2013909. https:\/\/doi.org\/10.1038\/sj.leu.2402890","journal-title":"Leukemia"},{"key":"3514_CR2","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/ijc.10557","volume":"100","author":"T Dreier","year":"2002","unstructured":"Dreier T, Lorenczewski G, Brandl C et al (2002) Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 100:690\u2013697. https:\/\/doi.org\/10.1002\/ijc.10557","journal-title":"Int J Cancer"},{"key":"3514_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.20908","volume":"115","author":"P Hoffmann","year":"2005","unstructured":"Hoffmann P, Hofmeister R, Brischwein K et al (2005) Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct. Int J Cancer 115:98\u2013104. https:\/\/doi.org\/10.1002\/ijc.20908","journal-title":"Int J Cancer"},{"key":"3514_CR4","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00262-007-0298-z","volume":"56","author":"C Brandl","year":"2007","unstructured":"Brandl C, Haas C, D\u2019Argouges S et al (2007) The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19\/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother 56:1551\u20131563. https:\/\/doi.org\/10.1007\/s00262-007-0298-z","journal-title":"Cancer Immunol Immunother"},{"key":"3514_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12864-021-07435-2","volume":"22","author":"Y Huo","year":"2021","unstructured":"Huo Y, Sheng Z, Lu DR et al (2021) Blinatumomab-induced T cell activation at single cell transcriptome resolution. BMC Genomics 22:1\u201316. https:\/\/doi.org\/10.1186\/s12864-021-07435-2","journal-title":"BMC Genomics"},{"key":"3514_CR6","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1182\/blood.v95.6.2098","volume":"95","author":"A L\u00f6ffler","year":"2000","unstructured":"L\u00f6ffler A, Kufer P, Lutterb\u00fcse R et al (2000) A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098\u20132103. https:\/\/doi.org\/10.1182\/blood.v95.6.2098","journal-title":"Blood"},{"key":"3514_CR7","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G et al (2014) Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32:4134\u20134140. https:\/\/doi.org\/10.1200\/JCO.2014.56.3247","journal-title":"J Clin Oncol"},{"key":"3514_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS et al (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16:57\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(14)71170-2","journal-title":"Lancet Oncol"},{"key":"3514_CR9","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/nejmoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376:836\u2013847. https:\/\/doi.org\/10.1056\/nejmoa1609783","journal-title":"N Engl J Med"},{"key":"3514_CR10","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1517\/14712598.2015.1041912","volume":"15","author":"B Rogala","year":"2015","unstructured":"Rogala B, Freyer CW, Ontiveros EP et al (2015) Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies. Expert Opin Biol Ther 15:895\u2013908. https:\/\/doi.org\/10.1517\/14712598.2015.1041912","journal-title":"Expert Opin Biol Ther"},{"key":"3514_CR11","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/s41375-020-01089-x","volume":"35","author":"AH Wei","year":"2021","unstructured":"Wei AH, Ribera JM, Larson RA et al (2021) Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia 35:2220\u20132231. https:\/\/doi.org\/10.1038\/s41375-020-01089-x","journal-title":"Leukemia"},{"key":"3514_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221142487","author":"Y Shimazu","year":"2022","unstructured":"Shimazu Y, Kanda J, Kaneko H et al (2022) Monocyte or white blood cell counts and \u03b22 microglobulin predict the durable efficacy of daratumumab with lenalidomide. Ther Adv Hematol. https:\/\/doi.org\/10.1177\/20406207221142487","journal-title":"Ther Adv Hematol"},{"key":"3514_CR13","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.1038\/S41598-023-32426-6","volume":"13","author":"Y Shimazu","year":"2023","unstructured":"Shimazu Y, Kanda J, Kosugi S et al (2023) Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa\/lambda ratio or B2 microglobulin. Sci Rep 13:5159. https:\/\/doi.org\/10.1038\/S41598-023-32426-6","journal-title":"Sci Rep"},{"key":"3514_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transpl 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transpl"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03514-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03514-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03514-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T07:02:40Z","timestamp":1697266960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03514-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["3514"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03514-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"6 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the other authors have no conflict of interest regarding to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving the patient were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The ethical approval was waived by Kyoto University Graduate School and Faculty of Medicine, Ethics Committee institutional because the data was provided as anonymized data and the ad-hoc nature of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}